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Many options now exist for constructing oral vaccines which, in experi-
mental systems, have shown themselves to be able to generate highly 
effective immunity against infectious diseases. Their suitability for imple-
mentation in clinical practice, however, for prevention of outbreaks, par-
ticularly in low- and middle-income countries (LMIC), is not always 
guaranteed, because of factors such as cost, logistics and cultural and 
environmental conditions. This brief overview provides a summary of the 
various approaches which can be adopted, and evaluates them from a 
pharmaceutical point, taking into account potential regulatory issues, 
expense, manufacturing complexity, etc., all of which can determine whether 
a vaccine approach will be successful in the late stages of development. 
Attention is also drawn to problems arising from inadequate diet, which 
impacts upon success in stimulating effective immunity, and identifies the 
use of lipid-based carriers as a way to counteract the problem of nutri-
tional deficiencies in vaccination campaigns.
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Introduction
The conditions predisposing to the emergence of new 
infectious diseases  –  close contact with animals, opening 
up of new territory, population growth, etc.  –  are par-
ticularly prevalent in tropical and low- to-middle-income 
countries, where infrastructure is often lacking to provide 
rapid and widespread implementation of vaccine pro-
grammes. Under such circumstances, vaccines in an oral 
form can help to tackle problems of logistics, often faced 
by parenteral vaccines, in a very effective manner.
While injected vaccines necessitate administration in 
an aqueous form, which is usually not stable to extremes 
of temperature, the solid-dose format of capsules or tablets 
lends itself to greater stability, which means that storage 
and transport can be effected without the need for cold-
chain procedures. Even injected vaccines in lyophilized 
form need to be reconstituted before use, which is not 
always a simple matter. Avoiding the use of needles also 
eliminates the possibility of contamination, and the need 
for rigorous containment measures, as well as supervised 
waste disposal, all of which are problematic for injected 
vaccines. Capsules take up little space, and are easily 
transported either in bulk or individually in blister packs. 
Administration does not need specialized medical skills, 
and the vaccine can even be taken home for self- 
administration at a later date.
Efficacy of oral vaccines
In spite of widespread agreement regarding the desirability 
of oral vaccination, the approach has met with consider-
able resistance up to the present day. This seems to be 
because of doubts regarding the efficacy of orally admin-
istered vaccines, and concerns that the immune response 
mounted after oral vaccination does not match that 
achieved by injection. In  reality, attempts to compare 
efficacy of injected and oral vaccines directly are not 
entirely valid, as the two routes initiate immunity in dif-
ferent parts of the body, and engender types of immunity 
different in qualitative rather than simply quantitative 
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terms. Live attenuated vectors given orally have long been 
known to induce good mucosal and systemic responses 
[1]. Non-living oral vaccines can do the same, now that 
technologies have advanced to target antigens to the 
immune cells in the gut and appropriate immunostimu-
lants are used [2,3]. In contrast, injected vaccines often 
afford poor levels of immunity in the intestine [4], so 
that their efficacy against intestinal pathogens is low in 
terms of providing a first line of defence, and the protec-
tion they offer only comes into play after the organism 
has crossed the gut wall and entered the body.
Under normal circumstances, antigens which enter the 
intestine are treated in the same way as dietary compo-
nents, where any potential immune response is suppressed, 
in order to avoid allergic reactions [5]. To generate a 
response in which the immune system is up-regulated, 
it is necessary to administer the antigen in conjunction 
with an immunostimulant. In the case of live vectors, or 
whole-killed organisms, this is provided by the organism 
itself  –  such as lipopolysaccharide [6] or cytosine–phos-
phate–guanine (CpG) [7]. In some instances, the antigen 
transferred into the vector may be specially engineered 
to incorporate immunostimulants or cytokines, secreted 
at the same time as the antigen, a strategy being explored 
extensively in cancer immunotherapy [8]. In non-living 
vaccine constructs, antigens can be combined with immu-
nostimulants possessing properties specifically adapted to 
the gut environment, of which the best known is cholera 
toxin B fragment (CTB), which binds specifically to GM1 
gangliosides on the cell surface, prior to ingestion of 
cholera toxin by the cell [9].
There is a general perception that mucosal immune 
responses are short-lived. This may, in part, be the result 
of observations on systemic immunity generated after oral 
administration, where cells produced by the gut appear 
in the bloodstream initially but migrate to other mucosal 
sites and focus their attention locally. In fact, antibody-
secreting cells in the gut mucosa have been demonstrated 
to persist for decades [10], and long-lived plasma cells 
provide long-lived mucosal immunity [11,12]. It has been 
noted that, in certain cases, cytotoxic T lymphocyte [13] 
and long-lived immunoglobulin (Ig)A mucosal memory 
[14] is more readily achieved via oral immunization than 
via systemic administration.
In addition, up-regulation of the immune response 
leading to significant long-term mucosal and systemic 
immunity can be readily achieved by supplementing with 
an additional oral boost. While there is an understandable 
reluctance to rely on boosters with injected vaccines, 
because of poor patient acceptability, it is important to 
rid the scientific community of this prejudice with regard 
to oral vaccination. Boosting is a natural mechanism 
whereby the body gradually increases its baseline immunity 
as a result of repeated exposure to antigens. In the case 
of oral administration, the objection of patients to repeat 
administration is removed, as a tablet or capsule is com-
pletely innocuous compared with an injection and can 
even be self-administered at the convenience of the patients 
themselves. For many conditions, even as simple as head-
aches, patients are happy to take pills several times a 
day, or once a day for extended periods of time, so the 
prospect of receiving a restricted number of booster 
administrations of an oral vaccine is in no way an impedi-
ment to the success of the oral vaccination approach. 
Provided that an immuno-upregulator is always combined 
with antigen, administration of a booster dose should 
not induce tolerance towards that antigen  (see further 
discussion later in this review).
The intestine is the largest immune organ in the body, 
acting as host to 70–80% of the body’s immune cells 
[15]. These cells can be located in one of several different 
environments to which vaccine carriers and their antigens 
can gain access: (i) the Peyer’s patches [16], highly struc-
tured lymphoid follicles specialized for initiation of immune 
responses through extensive antigen processing and pres-
entation on dendritic cells; (ii) the lamina propria, where 
lymphocytes (lamina propria lymphocytes, LPL) and den-
dritic cells are distributed throughout the lymphatic drain-
age channels; and (iii) mesenteric lymph nodes [17], into 
which lymphatics from the lamina propria flow; the same 
lymphatics can also feed ultimately into the peripheral 
systemic blood circulation via the thoracic duct. See refer-
ence [18] for an overview of the components of the gut 
immune system. An additional compartment, the intestinal 
epithelial layer itself, contains a large number of T cells 
(intraepithelial lymphocytes, IEL [19]) which perform 
important functions in maintaining the intestinal cell bar-
rier intact [20,21]. Both IEL and LPL comprise a large 
proportion of unusual T cell subsets, Tγδ cells, although 
the γδ populations in the two sites are functionally dif-
ferent, those in the lamina propria capable of secreting 
significant amounts of inflammatory cytokines such as 
interleukin (IL)-17 [22], while intestinal IEL T cell recep-
tor (TCR)-γδ cells (and TCR-αβCD8+) can secrete anti-
inflammatory cytokines such as IL-10 and transforming 
growth factor (TGF)-β [23,24]. It is likely, therefore, that 
IEL play a role in down-regulation of unwanted responses 
to non-pathogen-related antigens.
Oral vaccine carrier vehicles can access one or all of 
these sites (Fig. 1). Particulate materials (including viruses 
and bacteria) can be taken up by the M cells covering the 
Peyer’s patches, and such uptake can be enhanced by mak-
ing the particles lipidic in nature, or by placing on their 
surface ligands which can be recognized by M cells. Antigenic 
materials can also cross the intestinal cell barrier, either by 
passing through the cells (transcytosis) or in between them 
(paracellular transport though opening  of tight junctions). 
Recently, studies have indicated that antigens can be taken 
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Fig. 1. Routes of oral vaccine-delivered antigens through the intestine, accessing different parts of the immune system of the body. (1) Via 
microcapillaries into the local and peripheral blood circulation; (2) via the lamina propria and intestinal lymphatics into the mesenteric lymph nodes; 
(3) direct uptake though M cells into the Peyer’s patches.
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up by enterocytes via a phagocytic process [25,26]. It is 
also worth noting that the initial stage in the lipid-processing 
pathway of intestinal cells involves uptake of bile salt/oil 
micelles of approximately 0·4  mm diameter  –  the same 
size as particulate carriers discussed later. Antigen taken 
up via this route should survive intact, as the level of pro-
teases is low. After exocytosis from the enterocytes, the 
antigens and/or their carriers have opportunity to interact 
directly with itinerant memory T cells and phagocytes located 
in the lamina propia. The physicochemical nature of the 
antigen can determine the route in the body subsequently 
taken  –  small water-soluble molecules can diffuse across 
the semi-permeable membranes of blood microcapillaries 
and pass via the hepatic portal vein through the liver to 
the peripheral bloodstream, while large particulate and lipidic 
materials will be retained in the lymphatics (maximizing 
contact with intestinal lymphocytes) and then drain into 
the mesenteric lymph nodes, or eventually pass into the 
bloodstream via the thoracic duct.
Oral vaccines on the market
A number of oral vaccines are, or have been, on the 
market, details of which are listed in Table 1. The major-
ity of these are live attenuated organisms, the first and 
most well-known being the polio vaccine [27], an oral 
version of which, developed by Sabin [28], was first made 
available commercially in 1961. The first version of this 
vaccine comprised three separate strains (serotypes) attenu-
ated by sequential passage through a range of different 
monkey cell types derived from tissues such as skin, testicle 
and kidney [29]. This oral version was introduced after 
the majority of cases were already dramatically reduced 
by use of the original Salk inactivated polio vaccine, 
administered by injection, but the oral vaccine has played 
a major role in extending that decline as a result of the 
easier logistics of distribution and boosting, despite the 
issues with cold chains. Although polio has been eradi-
cated in all but three countries worldwide [30], a com-
bination of injected and oral vaccines have continued to 
be  employed in populations at potential risk to maintain 
herd immunity or to protect travellers.
Being the first live attenuated vaccine ever employed 
commercially, polio vaccine and its precursors ran into 
many teething troubles, such as contamination and rever-
sion, and even now vaccine-induced polio has been reported 
[31,32], although cases are far fewer than would be expected 
in an unvaccinated population. What has never been in 
doubt, however, is that the oral vaccine is highly effica-
cious in both adults and children, particularly in generating 
mucosal antibodies in the gut.
The polio virus does not specifically target immune 
tissues in the gut, but the attenuation process knocks out 
its ability to infect neural cells [33] while retaining its 
capacity for reproduction in intestinal epithelium [34]. 
Consequently, small doses of the live vaccine can result 
in rapid multiplication and secretion of large amounts of 
antigen, which are sufficient to trigger the intestinal immune 
system into action.
A second live attenuated viral vaccine has recently come 
onto the market: oral rotavirus vaccine, introduced first 
in the United States in 2006, and now used globally [35]. 
The protection rate varies markedly from study to study 
and country to country [36], but significant reductions 
in mortality are observed, and the vaccine can be given 
to children as young as 6  weeks of age.
Table 1. Oral vaccines in clinical use.
Infection Vaccine type Manufacturer Trade name
Poliomyelitis Live attenuated polio vaccine Many discontinued  
Rotavirus Live attenuated monovalent human rotavirus 
strain
GlaxoSmithKline Rotarix®
Live attenuated monovalent human rotavirus 
strain
Bharat Biotech Int. Ltd Rotavac®
Live attenuated monovalent human rotavirus 
strain
CRPVB, Vietnam Rotavin-M1®
Pentavalent live vaccine Merck & Co., Inc. RotaTeq®
Pentavalent live vaccine (lyophilized) Serum Institute (India) Rotasiil®
Typhoid Ty21a live attenuated vaccine Previously PaxVax Berna GmbH now 
Emergent Biosolutions
Vivotif®
Cholera Cholera toxin B subunit and inactivated V. 
cholerae 01 whole cells
Valneva Dukoral®
Live attenuated V. cholerae 01 strain  
(CVD 103.HgR)
PaxVax Vaxchora®
Additionally, oral  vaccines against adenovirus types 4 (Ad4) and 7 (Ad7) for prevention of febrile respiratory illness (FRI) are being produced by the US 
military for treatment of trainees. The vaccines are live attenuated viruses administered orally [109]. This table is not intended to be a comprehensive list.
Oral vaccines
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Two other marketed oral vaccines are both directed at 
bacterial targets: Salmonella enterica serovar typhi and 
Vibrio cholera. The live attenuated oral typhoid vaccine, 
Ty21a (Paxvax, introduced in 2014) appears to have similar 
efficacy to the injected Vi polysaccharide vaccine: ~50% 
protection after 3  years [37].
There are several different oral cholera vaccines on the 
market, some of which are live attenuated, and some are 
whole-killed bacteria. In the case of the whole-killed bate-
ria, manufactured by Valneva, the whole organism is 
supplemented with additional CTB, and large quantities 
are contained within each dose (Dukoral package leaflet 
information). CTB is a strong mucosal adjuvant [38–40], 
and this probably explains the efficacy of the vaccine even 
in the absence of an antigen-amplifying effect due to 
replication of live organisms in the gut. In the case of 
all the other vaccines (both bacterial and viral), however, 
even in the absence of a strong immunostimulants such 
as CTB, other immune triggers are present in the form 
of CpG (bacterial), single-stranded RNA or double-
stranded DNA, which bind to Toll-like receptors (TLR)-9, 
-7/8 and -3, respectively. One interesting aspect of the 
use of the cholera vaccines is the proposal that they can 
be employed reactively (i.e. after an outbreak has been 
initiated), rather than just in a prophylactic mode [41].
Experimental vaccines
Clearly, on the basis of the vaccines that are already being 
used in humans in large numbers for long periods of 
time, immunization via the oral route is a viable, effica-
cious and economic method of protecting against lethal 
diseases. Because of their more recent appearance, oral vac-
cines against emerging diseases are still in the experimental 
stage, and many different approaches are being explored. 
However, all these approaches share many features in 
common.
At the outset, it is important for several myths about 
challenges confronting oral vaccines to be dispelled. One 
is the barrier presented by the stomach. In fact, technolo-
gies for allowing agents to pass unharmed across the 
stomach have existed for decades, and are employed in 
a number of widely used pharmaceuticals. This involves 
filling the vaccine, in solid form, into capsules, which 
are coated with a polymer film (e.g. cellulose acetate 
phthalate, or Eudragit) which is insoluble at the low pH 
of the human stomach but dissolves readily at pH values 
above 5–5·5, after having passed unaltered into the small 
intestine. The common practice of presenting conventional 
vaccines in liquid form is one imposed by the need to 
inject into the body using a syringe. For oral vaccines, 
where the ingested antigen becomes dispersed in the liquid 
found in the lumen of the gut, presentation in solid form 
is more practical and promises higher levels of stability. 
Orally targeted vaccines are thus ideally suited for capsule 
or tablet administration.
The second myth is that the mucus layer covering the 
intestinal wall is a barrier to uptake. While this is true 
for absorption and uptake of materials via the enterocytes, 
the mucus layer covering the M cells of the Peyer’s patches 
is sparse or non-existent as the dome of the Peyer’s patches 
contains few, if any, goblet cells, so mucin secretion is 
greatly reduced. This is indeed to be expected, as it is 
the job of M cells to take up material of high molecular 
weight, which cannot easily diffuse across a thick mucus 
layer.
One generalization which holds for essentially all oral 
vaccine carriers and targeting vehicles is that the carrier 
should be particulate. Reasons for this are as follows:
(i)   M cells in the Peyer’s patches have a high propensity 
for uptake of particulates, the optimal size range 
centering approximately 0·1–0·2 mm in diameter;
(ii)   where ligands are employed to target the vaccine to 
structures on the surface of M cells, presentation of 
ligands as a multivalent array on the surface of a 
particle encourages internalization, compared with 
binding of ligands in a monomeric form;
(iii)  inclusion of both antigens and immunostimulants/
potentiators in the same particle ensures that these 
agents can reach the same cell and act in concert, 
rather than becoming physically separated during 
passage along the gut; and
(iv)  encapsulation within particles can protect protein 
antigens from attack and breakdown by intestinal 
proteases.
Live vectors
Attenuated bacteria. One type of particulate carrier 
which has received a great deal of attention is the live 
attenuated vector. This has the advantage that the quantity 
of antigen payload delivered can be amplified as a result of 
growth and limited replication inside the host, and that 
immunostimulants are co-expressed together with the 
antigens and targeting agents. The most successful ones to 
date are derived from pathogenic strains, as these have 
recognition structures which strongly stimulate the host 
immune system. Indeed, it is their pathogenicity which has 
caused the host to evolve specifically to recognize these 
structures. One vector which has been widely researched is 
the S. enterica serova typhi Ty21a attenuated strain, as this 
already has a long history of use in humans as a vaccine for 
typhoid fever.
Although good results have been obtained in animal 
experiments, studies in humans using strains expressing 
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heterologous antigens (i.e. antigens not native to the 
organism being used as vector) show that their efficacy 
leaves something to be desired [42]. One problem is that, 
because the vectors are originally pathogenic, great efforts 
are made to attenuate them, and in the process their 
immunogenicity may be reduced. A compounding issue 
is that introduction of foreign antigen into the vector, 
for in-situ production in a large quantity, takes its toll 
on the organism in terms of metabolic stress, so that the 
vectors are much less viable (particularly in an essentially 
hostile environment) when loaded with the additional 
burden of antigen production [43]. As a result, invasion 
and colonization, etc. are less effective. An ingenious way 
to overcome this is to manipulate the vector so that the 
antigen only starts being produced after the vector has 
penetrated the host tissues, enabling it to concentrate its 
energy on invasion, before a promoter kicks in (e.g. at 
low oxygen concentration) to start producing antigen after 
the organism has become well established. This and other 
promoters employed are summarized in da Silva et al 
[44]. Other issues needing attention are the locations in 
the bacterium of the genetic sequence. Larger amounts 
of antigen can be produced from plasmid-expressed DNA 
than chromosomal, but more care needs to be taken to 
ensure that plasmids are maintained from generation to 
generation and distributed evenly among daughter cells. 
This can be achieved by designing the plasmids so that 
they contain a gene essential for the survival of the whole 
organism (see review by Kotton & Hohmann [45] for a 
summary of approaches). An operator-repressor system 
(ORT) has also been developed for this purpose [46]. 
Finally, the protein may be engineered so that it either 
stays in the cytoplasm, becomes transferred to the peri-
plasmic space, is expressed on the outer membrane or 
is secreted. Each of these may result in a different type 
of immunity being generated [47]. In addition, the mag-
nitude of the immune response is not always linearly 
related to the dose of organism administered [48].
Encouraging results with bacterial vectors have been 
obtained using strong immunogens (e.g. diphtheria toxoid, 
Escherichia coli heat-labile toxin or tetanus toxoid frag-
ment C), each of which have their own adjuvanting capac-
ity, but responses in human clinical trials against ‘weak’ 
immunogens have so far been disappointing (see Galen 
et al. [38]). Further work on the issues described above 
may well change the situation.
Non-pathogenic bacterial vectors. The use of vectors 
which are commensal in the human gut, for which 
attenuation procedures are unnecessary, is an alternative 
approach which holds promise. As these organisms are 
adapted to the host intestine, they need to expend much 
less energy to survive and can devote all their efforts to 
production of antigens. The archetypal vectors of the class 
are members of the group of lactic acid bacteria, including 
lactobacilli and lactococcus species, as well as streptococci 
[49]. Although they are essentially non-pathogenic and 
can survive for long periods in the human gut, they can 
interact with the gut immune system and induce 
inflammatory reactions in dendritic cells, such as cytokine 
secretion and up-regulation of major histocompatibility 
complex (MHC) surface presentation molecules [50]. 
Lactobacilli can adhere to enterocyte membranes, thus 
preventing them from being cleared rapidly from the 
intestinal tract [51]. Their surface coat of poly teichoic 
acid (PTA) appears to be immunostimulatory, as mutants 
lacking PTA, but expressing foreign proteins, induce a 
suppressive response against that protein in the same way 
as does the gut immune system for food antigens [52]. 
Different strains of lactobacilli (e.g. casei, acidophilus, 
gassneri) stimulate the immune system in different ways, 
leading to different types of immune response, so there is 
the possibility of matching the immunity generated to the 
organism being targeted [53,54].
Other lactic acid bacteria which have been the subject 
of much study are lactococci (e.g. lactococcus lacti), which 
do not have as long a residence time in the gut as lac-
tobacilli, or are immunostimulatory to the same extent, 
but seem to be able to produce large quantities of antigen 
and are easy to manipulate genetically. Some strains have 
been engineered so that they can be internalized by mam-
malian cells, and as such can act as vectors for DNA 
vaccines [55].
Viral vectors. Viruses are also good candidates as 
vectors for vaccine antigens. Adenoviruses in particular 
can withstand the environment of the gut, and can infect 
intestinal cells [56]. Their replication mechanisms can be 
employed to insert antigens onto cell membranes, and this 
generates strong T cell immune responses, which can be 
enhanced [57]. Because space within a virus capsid is 
limited, insertion of large amounts of genetic material 
may not always be easy. Another concern is that pre-
existing immunity to the viral carrier may impair their 
ability to function as vaccines, particularly if a booster is 
required [58]. Although experiments in rodents suggested 
that pre-existing immunity (acquired in the form of 
maternal antibody) was not a problem [59], a dose-
ranging study in humans showed that those subjects with 
antibodies against the carrier developed significantly 
reduced responses against the foreign antigen at lower 
doses of virus, but that as the dose was increased, existing 
immunity no longer influenced the outcome [60]. 
Whether or not dosing at the high levels reported is 
routinely feasible is an issue which needs careful 
examination.
One solution to the problem of pre-existing immu-
nity  –  or more specifically, the avoidance of generating 
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immunity against the carrier in a priming administration 
which then inhibits a booster response  –  is to use dif-
ferent carriers for the prime and booster. This approach 
provides two shots at generating specific types of immunity 
adapted to the target, and was employed successfully in 
rodents, generating responses T and B cell responses 
against HIV antigen through the use of attenuated  oral 
Listeria monocytogenes, followed-up with the AD4 admin-
istered intra-vaginally [61]. The complexity of the system, 
however, will be a significant obstacle to implementation 
in clinical practice.
An alternative method of circumventing the effects of 
pre-existing immunity is to mask the surface of the virus 
so that antibodies are unable to bind. This has been 
achieved by coating the virus covalently with liposomes 
[62]. Under these circumstances, the normal method of 
entry of the virus is probably blocked, but this can be 
overcome by making the liposomes cationic, which pro-
vides a mechanism for targeting to the cell surface and 
aids internalization. Thereafter, replication is able to proceed 
normally, although subsequent cell-to-cell transfer would 
be inhibited, which may be a good safety mechanism.
The underlying concern with all approaches involving 
live vectors is the lack of control over the replication 
process once ingested and the possibility of reverting to 
a pathogenic form, either by spontaneous mutation or 
acquisition of new genes from environmental flora. In 
the case of polio, the incidence of reversion was low, but 
finite, and the possibility that similar events can occur 
with other, less well-researched vectors, cannot be ruled 
out. Consequently, in many countries, regulatory authori-
ties are still very reluctant to approve introduction of 
vaccines based on live vectors, and their perception as 
methodologies still in the experimental phase is a reason 
for resistance to their introduction from the West into 
low- and middle-income countries (LMIC) for emerging 
diseases. The absence of such safety concerns is one reason 
for continued focus on non-living carriers for antigen 
delivery in vaccines for emerging diseases. Here, the anti-
genic material can either be whole-killed organisms or 
subunits thereof, and the need for containment procedures 
and avoidance of contamination is markedly reduced.
Non-living vaccines
Foodstuffs. The recognition that foodstuffs are materials 
which are highly compatible with the intestinal tract, and 
that plants can be employed to synthesize proteins easily in 
large quantities, has led to the suggestion that certain foods 
could be used as agents for delivering antigens orally as 
vaccines [63]. A number of studies showed success using 
CTB or E. coli toxin fragment as antigen [64,65], but these 
cannot be considered as demonstrations of enhanced 
delivery to the immune system, as CTB/ETB are 
immunostimulatory in their own right in the absence of any 
carrier system, provided that a sufficiently large amount of 
proteins is ingested. Using the same approach with other 
antigens could risk inducing suppression of immune 
responses to the antigen rather than stimulation, unless 
something such as CTB were administered at the same time. 
An extension of this approach might be to work with fusion 
proteins of antigen and CTB together. In both cases, 
however, immunity against bystander molecules could be 
generated as a result of unanticipated physical association 
with the CTB molecule, as no provision is made for 
encapsulation to restrict such non-specific interactions. 
Even if antigen and immunostimulant were to be co-
encapsulated with a food granule (e.g. yeast-derived beta-
glucan particles [66]) a mechanism for targeting to Peyer’s 
patches would still be required. Work directed towards use 
of foodstuff-based vaccines as a general principle is now 
focusing on plants as a method of antigen production, rather 
than in-vivo delivery of antigen.
Encapsulation vehicles. The advantage of building a 
carrier using pharmaceutical principles ‘from the ground 
up’ is that one has freedom to incorporate any number of 
specific agents (immunostimulants, immunopotentiators, 
etc.  –  see Table 2) permitting one to induce an immune 
response tailored specifically to the infectious organism 
being targeted. As time progresses, more and more such 
agents will be identified, which can lead to ever more 
sophisticated vehicles targeting only the right arms of the 
immune response at the right time. Even with the current 
range of stimulators available (see Table 2) strong and 
specific responses can be brought about in a number of 
ways. In addition, encapsulation within a carrier prevents 
the antigen being broken down by gut digestive processes 
before reaching the immune system, and permits targeting 
ligands to be attached to the outside of the particle to 
enhance uptake by the gut immune system, particularly the 
Peyer’s patches (see Table 3).
As mentioned above, inclusion of a strong immu-
nostimulant is key to ensuring that suppression of the 
immune response to administered antigen does not occur. 
To date, the most successful and widespread stimulant 
employed for this purpose is CTB [67]. This is present 
in the oral cholera vaccine Dukoral™, providing a history 
of safe oral use in humans. Immune responses and pro-
tection in cholera models have been demonstrated with 
recombinantly produced CTB [68,69], and strong responses 
to other antigens are generated when co-administered 
with recombinant CTB [70,71], confirming that the effect 
is due to the presence of CTB alone, and not the pres-
ence of low levels of cholera toxin A fragment (CTA).
One should be aware that a great deal of work has 
been performed using CTB as an agent to induce 
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antigen-specific tolerance [72]. Almost invariably, however, 
this is observed when the antigen is linked covalently (or 
fused) to CTB, rather than simply co-administered. Why 
the CTB behaves in this altered  fashion is not clear, 
although it is to be expected that attaching exogenous 
molecules at certain sites may prevent polymerization 
which may change its interaction with lipid rafts, even 
though binding to GM1 is maintained [73]. It may also 
be that other sites on the surface of the molecule are 
masked by the antigen, interfering with its stimulatory 
effect. Occasions have been reported where free CTB 
administered orally can tolerize, although this is when 
the CTB comes into contact with the gut milieu and the 
proteases therein, so it is likely that structural modifica-
tions have taken place. This is an additional argument 
for administering CTB in encapsulated form, where contact 
with extracellular protease will be avoided. It is worth 
mentioning in passing that conjugation of antigens to 
CTB or E. coli EtxB does not always lead to tolerance. 
Polysaccharides conjugated chemically to EtxB gave a 
construct which stimulated generation of antibodies to 
polysaccharide in both serum and stools of mice after 
oral administration [74].
Three types of synthetic vaccine carrier suitable for the 
gut environment have been studied, their physical char-
acteristics being illustrated in Fig. 2. Membrane vesicles 
such as liposomes have been employed since the 1970s, 
following observation that these carriers worked well after 
parenteral administration. In parallel, polymeric particle 
matrices have been extensively researched, including PLGA 
and chitosan nanoparticles. Finally, oil droplet-based vehi-
cles have shown promise, and for reasons described later 
may come to be the method of choice for synthetic car-
riers. All these vehicles are constructed from  generally-
recognized-as-safe (GRAS)-listed materials, with good safety 
profiles, so regulatory requirements can easily be met and 
toxicity is unlikely to be an issue. Methods of manufacture 
on a commercial scale have been established for many 
years, and use standard, non-specialized equipment, so 
technology transfer and production plants can be set up 
anywhere in the world.
Table 2. Targets of immunostimulants employed in vaccines.
Target Agent References
TLR-2 Mannan, zymosan, beta-glucan, 
muramyl dipeptide (MDP)
[110–112]
TLR-2/1 Bacterial lipopeptide; Pam3CSK4 [113–115]




TLR-4 LPS, glycoinositol phospholipids, 




TLR-6 Zymosan, beta-glucan [124]
TLR-7, TLR-8 ssRNA; imiquimod [125–127]
TLR-9 CpG DNA [128]
GM1 Cholera toxin B fragment (CTB),  




NOD1 NOD2 Muramyl dipeptide (MDP) [129]
STING cGAMP [130]
IL-1 receptor IL-1 [131]
IL-7, IL-12 and 
IL-15 
receptors
IL-7, IL-12, IL-15 [132]
Mincle Trehalose dibehenate (TDB) [133]
See Hug et al.[134] for a general review on Toll-like receptors (TLR) 
in relation to the human gut.
CpG = cytosine–phosphate–guanine; IL = interleukin; LPS = lipopol-
ysaccharide; NOD = non-obese diabetic.
Table 3. Ligands targeting to Peyer’s patch M cells.
Target Ligand Ref
Lectin targets    
lectin α1,2 fucose UEA-1 [135,136]
α-L-fucose Aleuria auranitia (AAL) [137]
 (D-glcNAc)2,sialic 
acid






Microbial targets    
β1 integrin Invasin (Yersinia) [140,141]
Glycoprotein 2 IgA 
immunogloblin 
receptors
FimH (E. coli, Salmonella) [142–144]
C5aR OmpH (Yersinia) [145]
Cellular prion protein Hsp60 of Brucella abortus [146]




PGLRP-1 Bacterial peptidoglycan [148]





α2,3 sialic acid σ1 protein (reovirus) [150]
PFAR Phosphorylcholine moiety 
of LPS
[151]




P2X7 receptor, formyl 
peptide receptor 2
Cathelicidin LL-37 [153]
Data drawn from tables in Pandit et al. [2] and Kim et al. [3].
LPS = lipopolysaccharide.
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Fig. 2. Different types of particulate carrier employed as oral vaccine vehicles. (1) Membrane vesicles (liposomes); (2) polymeric micro/nanoparticles; 
(3) oil droplets and emulsions.
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Liposomes. Liposomes are well established as pharma-
ceutical carriers, and have been on the market for parenteral 
administration in applications such as cancer chemotherapy 
and treatment of candidiasis [75]. They are membrane vesi-
cles in which the membrane is generally made up of compo-
nents similar to those in natural cell membranes (principally 
phospholipids) and, for this reason, they are considered to 
be highly compatible with biological systems. The amphi-
philic nature of phospholipids means that they are suitable 
for incorporating a wide range of hydrophilic and hydro-
phobic components. Thus, water-soluble antigens can be 
encapsulated  within the aqueous space enclosed by the 
membrane, while membrane-associated antigens (e.g. viral) 
and lipidic immunostimulants such as cord factor, muramyl 
dipeptide or lipopolysaccharide can be held within the 
membrane itself. To fulfil such requirements, multi-lamellar 
vesicles are the most appropriate to employ as they have 
roughly equal proportions of hydrophilic and lipophilic 
space within the vesicles. Their size can be tailored by extru-
sion through controlled-pore membrane filters, and they are 
physically more stable to lyophilization than are liposomes 
composed of just one single outer membrane.
Liposomes composed of commonly available phospho-
lipids (phosphatidyl choline from egg or soya) are unstable 
in the gut environment, being prone to breakdown by 
bile salts and phopholipases. Consequently, alternative 
lipids are often used, which give more robust membranes 
resistant to enzymic attack  –  for example, synthetic dis-
tearoyl PC, sphingomyelin or archebacterial lipids, where 
the amphiphile is double-headed, and spans both sides 
of the ‘bilayer’ membrane. Use of such lipids complicates 
the manufacture process, however, and incorporation of 
encapsulants is not 100%, so purification procedures need 
to be conducted, followed by extensive characterization 
to make sure that consistency is maintained from batch 
to batch. Successful generation of oral immune responses 
has been reported in a number of disease models [76]. 
See Corthésy et al. for a general review of lipid-based 
particles as mucosal vaccine adjuvants, including the oil 
droplet approaches described here later [77].
A variant of liposomes, ISCOMs (Immune Stimulating 
COMplexes), in which phospholipids are co-formulated 
with an immunostimulatory saponin amphiphile, has 
shown promise as a vaccine vehicle, inducing strong 
humoral and T cell responses after parenteral administra-
tion [78,79]. The vesicles are small and contain little 
internal aqueous space, so antigens incorporated into 
ISCOMs are usually inserted into the outer membrane. 
As such, the vehicle was originally considered best suited 
for presentation of viral and other membrane-bound anti-
gens. In fact, however, it emerges that good immune 
responses are generated even if antigens are not physically 
incorporated into the ISCOMS [80] so, under some 
circumstances, use with a wider range of antigens can 
be envisaged.
A small number of studies have been conducted [81–83], 
with some success, looking at ISCOMs administered orally, 
although the authors indicated that high doses of antigen 
were administered [84]. It should be noted that intrinsic 
properties of the vehicle may limit its applicability via 
the oral route  –  namely, that the vesicles are labile and 
readily disassembled by detergents in the gut, that anti-
gens  which are not incorporated physically into ISCOMs 
can be easily separated from the immunostimulant by 
dilution in intestinal fluid, that antigens presented on the 
surface are exposed to protease attack, and that the anti-
gens incorporated into ISCOMs are restricted to the subset 
which is membrane-bound. Finally, the saponins in par-
ticulate form display toxicity to many cancer cells and, 
to a lesser extent, to normal cells [85], so there may be 
regulatory issues which need to be addressed.
Polymeric particulates. Recent studies conducted with 
thiol organosilica nanoparticles have shown that these can 
be taken up spontaneously by Peyer’s patches via transcytosis 
through M cells, and that optimal uptake was dependent on 
their size [86]. A diameter of 0·1 μm seems to be preferred, 
although larger particles could also be taken up to lesser 
extents, probably via a different mechanism. Other workers 
looked at uptake of hydrophobic latex particles by Peyer’s 
patches, and also found that sub-micron particles were 
taken up preferentially [87]. Coating the particles with block 
co-polymers to confer a hydrophilic surface to the particles 
inhibited uptake, showing that M cells have a natural 
preference for uptake of hydrophobic particles. Uptake of 
hydrophilic particles bearing charge, however, either 
positive or negative, has also been observed, implicating 
non-specific interactions with certain surface-bound 
receptors. It is worth mentioning as an aside that, although 
liposomes are composed of lipids (particularly 
phospholipids) they cannot be considered to be hydrophobic, 
as it is their highly polar phosphoryl choline headgroups 
which are outermost on the vesicle, presenting a very 
hydrophilic surface. Inclusion of specific targeting ligands 
on the outside of liposomes is therefore to be recommended 
in order to achieve uptake by Peyer’s patches.
Under the right circumstances, polymeric particles seem 
to be able to access Peyer’s patches unaided, which makes 
their cost lower and facilitates manufacture. They are also 
stable in the dry form, and can easily be reconstituted 
in aqueous media. A potential issue with polymeric par-
ticles, however, is their disintegration kinetics. They need 
to be able to break down in order to release their contents 
when inside the cell. Conversely, their disintegration should 
not be so rapid that they come apart in the intestinal 
lumen before reaching the Peyer’s patches. A fine balance 
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needs to be struck, therefore. Other concerns are that 
large amounts of either hydrophilic or hydrophobic 
agents  encapsulated within the body of the particle may 
disrupt the matrix and alter the disintegration kinetics, 
or that the matrix may disrupt the antigen  itself and 
cause deleterious structural changes. A final problem is 
that the particles may not be so versatile in the nature 
and number of encapsulants they can hold; small mol-
ecules may leak out of the matrix while large proteins 
are held back. This is not a concern when used as drug 
delivery vehicles, where incorporation of a single agent 
is all that is required. For vaccines, however, inclusion 
of a large number of different components is desirable, 
as these can synergize to stimulate the immune system 
to best effect, and it may not be possible, in polymeric 
particles, to control the behaviour of all these agents 
optimally at the same time.
The material of choice for construction of microparticles 
for use in vivo is poly lactic glycolic acid (PLGA) [88], 
as this is biodegradable and has a long history of use in 
clinical practice. The hydrophilic/hydrophobic balance of 
these particles can be controlled by varying the ratio of 
lactic/glycolic acids employed. In addition, PLGA particles 
have been constructed using coatings such as polymethyl 
methacrylate [89] or containing TLR agonists such as 
monophosphoryl lipid A (MPLA), CpG and Pam3-Cys-
Ser-Lys4 (Pam3CSK4) [90]. Microparticles constructed of 
chitosan have also been investigated, as chitosan has 
immunostimulating properties in its own right, because 
of its polycationic nature [91]. For comprehensive reviews 
of the performance of polymeric particles in disease models 
see references [92,93].
Oil droplets. The recognition that Peyer’s patch M cells 
have a predilection for hydrophobic particulates leads to 
the realization that the archetypal hydrophobic particle – an 
oil droplet  –  may also have potential as an oral vaccine 
carrier. This particularly makes sense bearing in mind that 
oils have been used as the basis for parenteral adjuvant 
formulations for decades, at least in experimental studies, 
in the form of Freund’s complete and incomplete adjuvants, 
where mineral oil is taken up by phagocytic cells, and 
appears to have a stimulating effect in its own right. A 
number of oil-containing injectable vaccines are currently 
on the market, but in these formulations the antigen is 
located outside the oil droplets. For formulations 
administered orally, where the antigen needs to be protected 
from digestive enzymes and carried by the droplets to 
Peyer’s patches, the antigen must be encapsulated within 
the oil phase itself, a requirement which presents a 
challenge, as protein antigens are generally hydrophilic 
while the oil is hydrophobic. Two strategies have been 
employed to overcome this fundamental incompatibility.
The standard approach is production of what are known 
as double emulsions, where an aqueous phase is dispersed 
as droplets in an oil medium which is then itself dispersed 
in an aqueous phase [94]. Different amphiphiles stabiliz-
ing the two types of droplet are required to facilitate 
their formation, as the relative size of head group and 
lipid tail varies in each case. Much energy needs to be 
expended to make the water-in-oil droplets small enough 
to fit into the final oil droplet of 0·2  mm diameter or 
less. Success has been achieved in generating immune 
responses after oral administration [95]. However, use of 
these formulations in commercial practice may be dogged 
by stability issues, as there is the possibility of leakage 
of antigens from the core droplets, either during manu-
facture or storage; in addition, the presence of free water 
in the aqueous droplets raises the possibility of hydrolytic 
degradation of antigen, meaning that a cold chain is 
required during storage and distribution.
These problems are overcome by a more recent for-
mulation methodology in which the antigens are incor-
porated into the oil phase not inside water droplets but 
within reverse micelles [96]. Indeed, the technique 
employed is to form the reverse micelles first, and then 
dissolve them in the oil to form a clear solution. The 
end result is an antigen-containing oil phase which can 
self-emulsify in water (for example, in the lumen of the 
gut) to form droplets of the right size. Minimal leakage 
occurs during the self-emulsification process and, interest-
ingly, the same amphiphiles which emulsify the oil into 
droplets are also suitable for the formation of reverse 
micelles. No free water is present in the reverse micelles 
(this is taken off during lyophilization) so a cold chain 
should not be needed, as the threat of hydrolytic degra-
dation is minimized. The absence of water also means 
that the bulk oil phase can be filled into a capsule for 
ease of administration. Unlike all the other particulate 
formulations described here, the method of manufacture 
involving reverse micelles dictates that incorporation is 
100%, thus avoiding wastage and simplifying purification 
and characterization procedures. These formulations have 
been employed successfully in a number of preclinical 
disease models [68,97], including challenge studies [98], 
and are ready for testing in the clinic.
One big advantage that the oil-based formulations 
have over other types of carrier is that they can stably 
incorporate a large variety of different immunopotentia-
tors in large quantities. These include the fat-soluble 
vitamins A, D and E, all of which are known to play 
important roles in support of responses generated in 
the intestinal mucosa. While liposomes can, in, theory 
incorporate these agents into their membranes, large 
amounts will destabilize the membrane so their ability 
to deliver them is limited. Vitamin E, in oil-based 
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vaccine formulations, increases antibody responses and 
modulates expression of interleukins such as IL-6, and 
chemokines belonging to CC and CXC classes, as well 
as aiding recruitment of granulocytes [99]. Vitamin A, 
specifically retinoic acid, enhances the ability of dendritic 
cells to present antigen [100], encourages the produc-
tion of cytokines promoting a T helper type 1 (Th1) 
response [101] and influences the homing [102] response 
of cells  –  in this case the ability of lymphoid cells to 
return to mucosal tissues after having migrated from 
Peyer’s patches or mesenteric lymph nodes [103]. Vitamin 
D plays an important role in controlling T cell devel-
opment in the later stages of immune stimulation [104], 
and in particular increases the pool of memory T cells 
in infectious disease [105]. An oral lipid formulation 
containing all those vitamins in combination has been 
reported in Moore et al. [106], demonstrating success-
fully the boosting of an immune response against plague 
(Yersinia pestis antigens F1 and V). This work has also 
pioneered a combination of injected prime and oral 
booster, as a rapid way of maximizing responses to the 
disease.
The role played by these (and other) dietary compo-
nents in the proper working of the immune system 
makes it clear that adequate nutrition is an important 
prerequisite for generating strong immune responses. 
Unfortunately, in LMIC, malnutrition of populations at 
risk is a serious problem [107,108], and the correlation 
between famine and rise of epidemic disease is well 
accepted. Clearly, a vaccine which is able to supply 
these micronutrients at the right place, and at the right 
time (i.e. during initiation of an immune response), is 
a very desirable objective, and this is an extremely sig-
nificant advantage of oil-based oral vaccines for protec-
tion against emerging diseases.
Conclusion
There is no reason to believe that new infectious diseases 
will not continue to emerge in the future, and the likeli-
hood is that these will appear in their severest form in 
LMICs, where climate, living standards, public health 
issues and poor nutrition combine to increase transmis-
sion, and weaken natural immune resistance. The new 
generations of vaccine developed for combatting these 
diseases need to be ones which can perform well in such 
an environment, i.e. can be stored and distributed easily, 
are readily acceptable by the local population, can easily 
be handled by non-medical personnel with risk of con-
tamination and show clear evidence of efficacy. These 
criteria are all fulfilled by oral vaccines, and future ini-
tiatives designed to tackle the problems of emerging 
diseases, particularly in LMIC, must make oral vaccina-
tion a high priority.
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